Melphalan and purine analog–containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation
Sergio Giralt(Memorial Sloan Kettering Cancer Center), Richard E. Champlin(The University of Texas MD Anderson Cancer Center), Börje S. Andersson(The University of Texas MD Anderson Cancer Center), James Gajewski(The University of Texas MD Anderson Cancer Center), J Bruton(The University of Texas MD Anderson Cancer Center), Cindy Ippolitti(The University of Texas MD Anderson Cancer Center), Steven M. Kornblau(The University of Texas MD Anderson Cancer Center), Ira Braunschweig(The University of Texas MD Anderson Cancer Center), Issa F. Khouri(The University of Texas MD Anderson Cancer Center), Donna Przepiorka(The University of Texas MD Anderson Cancer Center), Jeff Molldrem(The University of Texas MD Anderson Cancer Center), Michael Andreeff(The University of Texas MD Anderson Cancer Center), Paolo Anderlini(The University of Texas MD Anderson Cancer Center), Naoto T. Ueno(Breast Cancer Care), Xuemei Wang(The University of Texas MD Anderson Cancer Center), Michèle L. Donato(The University of Texas Health Science Center at Houston), Agueda Cohen(The University of Texas MD Anderson Cancer Center), Peter F. Thall(The University of Texas MD Anderson Cancer Center), M. Davis(The University of Texas MD Anderson Cancer Center), David F. Claxton(The University of Texas MD Anderson Cancer Center)
Cited by 516
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k
CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION
|British Journal of Haematology|1998|1.5k
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
|Journal of Clinical Oncology|1997|1.3k